STOCK TITAN
  1. Home
  2. News
  3. COSM

Cosmos Health Inc - COSM STOCK NEWS

Welcome to our dedicated news page for Cosmos Health (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cosmos Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cosmos Health's position in the market.

News
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
Rhea-AI Summary
Cosmos Health, a global healthcare group, received a notification from Nasdaq for the late filing of its Form 10-K. The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1) but has 60 days to submit a plan to regain compliance. The CEO is optimistic about resolving the issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
-
News
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
Rhea-AI Summary
Cosmos Health Inc. announces the development of Cloudscreen 2.0, an advanced AI drug repurposing platform, following the acquisition of Cloudscreen. The new platform utilizes cutting-edge AI and machine learning technologies to predict drug-protein interactions across the human proteome's structural landscape. By integrating mutagenesis data and prediction tools for disordered proteins, Cloudscreen 2.0 aims to revolutionize drug repurposing with more robust predictions and higher confidence scores. Greg Siokas, CEO of Cosmos Health, anticipates significant positive outcomes from Cloudscreen 2.0.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
AI
-
News
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
Rhea-AI Summary
Cosmos Health Inc. announces final stages of securing regulatory approval to sell biocide disinfectant hand soap, C-Scrub Wash 4% CHG, in the UK. The Company expects to enter agreements to supply the NHS, targeting a significant market share. C-Scrub offers immediate and prolonged antimicrobial action, catering to a wide range of microbes, with a focus on skin health and cosmetic friendliness. The global hospital disinfectant market is projected to grow significantly, positioning Cosmos Health for potential growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
News
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
Rhea-AI Summary
Cosmos Health Inc. has received regulatory approval to sell its Sky Premium Life vitamins and food supplements in the UAE market, with a projected market growth to $3.94 billion by 2030. The company aims to secure an exclusive distribution agreement and increase revenue through expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
none
-
News
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
Rhea-AI Summary
Cosmos Health Inc. announces the successful acquisition of Pharmatrade S.A.'s distribution network, aiming to boost 2024 revenue by $5 million and improve operational efficiencies through synergies with CosmoFarm Pharmaceuticals S.A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
acquisition
-
News
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
Rhea-AI Summary
Cosmos Health Inc. receives a Speculative Buy rating and a $4.00 price target from Taglich Brothers, indicating substantial growth potential. The company's revenue is expected to reach $64 million in FY 2024, with a focus on vertical integration and global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
earnings
News
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
Rhea-AI Summary
Cosmos Health Inc. CEO, Mr. Greg Siokas, demonstrates his confidence in the company by acquiring 60,000 shares at $0.8301 each, totaling $49,806. Siokas plans to invest up to $3 million in shares by 2024. Despite significant company progress, Siokas believes the stock is undervalued, emphasizing commitment to enhancing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
Rhea-AI Summary
Cosmos Health Inc. announced that Taglich Brothers, Inc. has initiated coverage of the Company's common stock. Taglich Brothers is a full-service broker dealer with a focus on microcap companies. The coverage and associated reports will be available at www.taglichbrothers.com. Cosmos Health CEO, Greg Siokas, stated that the company has accomplished multiple milestones, including transforming its balance sheet, completing strategic acquisitions, enhancing production facilities, launching new brands, filing patent applications, and establishing a portfolio of generic drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
News
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
Rhea-AI Summary
Cosmos Health Inc. has successfully completed the acquisition of Cloudscreen, a cutting-edge AI-powered platform specialized in drug repurposing. Cloudscreen's AI algorithm integrates 1D and 3D data to provide accurate predictions for existing drugs towards new indications, offering higher success rates, heightened safety profiles, and significantly shorter impact times compared to traditional drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
acquisition AI
News
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
Rhea-AI Summary
Cosmos Health Inc. has completed the acquisition of a portfolio of 10 generic drugs, enhancing its pharmaceutical portfolio. The acquisition cost €3.2 million, and the global generic drugs market is projected to reach $613.34 billion by 2030. Cosmos Health aims to capture a substantial share of this market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
acquisition
Stock COSM logo
Cosmos Health Inc

Nasdaq:COSM

COSM Rankings

N/A Ranked by Market Cap
#4 Ranked by Stock Gains
N/A Ranked by Dividends

COSM Stock Data

11.88M
10.69M
13.05%
11.61%
3.25%
Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
Wholesale Trade
Link
United States
Chicago